Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 5/20 | 0.54 |
| ▸ | MEN1 | O00255 | 1/20 | 0.54 |
| ▸ | ABL1 | P00519 | 1/20 | 0.54 |
| ▸ | LMNA | P02545 | 1/20 | 0.54 |
| ▸ | PKM | P14618 | 1/20 | 0.54 |
| ▸ | IDE | P14735 | 1/20 | 0.54 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.54 |
| ▸ | RIN1 | Q13671 | 1/20 | 0.54 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.54 |
| ▸ | HLCS | P50747 | 6/20 | 0.53 |
| ▸ | CA12 | O43570 | 7/20 | 0.41 |
| ▸ | CA1 | P00915 | 7/20 | 0.41 |
| ▸ | CA2 | P00918 | 7/20 | 0.41 |
| ▸ | CA9 | Q16790 | 7/20 | 0.41 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6394025 | 0.91 | HLCS (0.66) | TDP1MEN1ABL1LMNAPKM | |
| SCHEMBL14905687 | 0.90 | TDP1 (0.69) | TDP1MEN1ABL1LMNAPKM | |
| SCHEMBL1270219 | 0.90 | TDP1 (0.60) | TDP1MEN1ABL1LMNAPKM | |
| SCHEMBL3924414 | 0.89 | TDP1 (0.70) | TDP1MEN1ABL1LMNAPKM | |
| Bromide SCHEMBL2125952 | 0.89 | TDP1 (0.59) | TDP1MEN1ABL1LMNAPKM | |
| SCHEMBL1527196 | 0.86 | TDP1 (0.58) | TDP1MEN1ABL1LMNAPKM | |
| SCHEMBL4454446 | 0.86 | TDP1 (0.58) | TDP1MEN1ABL1LMNAPKM | |
| SCHEMBL4740139 | 0.85 | TDP1 (0.60) | TDP1MEN1ABL1LMNAPKM | |
| SCHEMBL9194081 | 0.84 | TDP1 (0.48) | TDP1MEN1ABL1LMNAPKM | |
| SCHEMBL2350071 | 0.83 | TDP1 (0.60) | TDP1MEN1ABL1LMNAPKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7816388-B2 | Biotin diaminoderivatives and their conjugates with macrocyclic chelating agents | SIGMA-TAU INDUSTRIE FARMACEUTICHE RIUNITE S.P.A. (IT) | 2010-10-19 | — | — | US | disclosed |
| EP-1928508-B1 | BIOTIN DIAMINODERIVATIVES AND THEIR CONJUGATES WITH MACROCYCLIC CHELATING AGENTS | SIGMA TAU IND FARMACEUTI (IT) | 2009-11-11 | — | — | EP | disclosed |
| US-20080249152-A1 | Biotin Diaminoderivatives and Their Conjugates With Macrocyclic Chelating Agents | SIGMA-TAU INDUSTRIE FARMACEUTICHE RIUNITE S.P.A. (IT) | 2008-10-09 | — | — | US | disclosed |
| EP-1928508-A1 | BIOTIN DIAMINODERIVATIVES AND THEIR CONJUGATES WITH MACROCYCLIC CHELATING AGENTS | SIGMA-TAU Industrie Farmaceutiche Riunite S.p.A. (IT) | 2008-06-11 | — | — | EP | disclosed |
| WO-2007039437-A1 | BIOTIN DIAMINODERIVATIVES AND THEIR CONJUGATES WITH MACROCYCLIC CHELATING AGENTS | SIGMA-TAU INDUSTRIE FARMACEUTICHE RIUNITE S.P.A. (IT) | 2007-04-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080249152-A1 | Biotin Diaminoderivatives and Their Conjugates With Macrocyclic Chelating Agents | BTD, HLCS, SLC19A2 | TDP1 2934/4885MEN1 136/4885ABL1 3222/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.